Evidence map›Paper›PMID 40806287›Full record

ArticleInternational journal of molecular sciences2025

Feasibility of Manufacturing and Antitumor Activity of TIL for Advanced Endometrial Cancers.

Yongliang Zhang, Kathleen N Moore, Amir A Jazaeri, Judy Fang, Ilabahen Patel, Andrew Yuhas, Patrick Innamarato, Nathan Gilbert, Joseph W Dean, Behzad Damirchi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yongliang ZhangIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Kathleen N MooreStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Amir A JazaeriUniversity of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Judy FangIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Ilabahen PatelIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Andrew YuhasIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Patrick InnamaratoIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Nathan GilbertIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Joseph W DeanIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Behzad DamirchiIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Joe YglesiasIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Rongsu QiIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Michelle R Simpson-AbelsonIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Erwin CammaartIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Sean R R HallIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.
Hequn YinIovance Biotherapeutics, Inc., San Carlos, CA 94070, USA.

Funding

Iovance Biotherapeutics Inc. N/A
6 · The paper itself

Abstract

Lifileucel, a tumor-infiltrating lymphocyte (TIL) cell therapy approved for advanced melanoma, demonstrates promise for treating other solid tumors, including endometrial cancer (EC). The current study evaluates the feasibility of manufacturing TILs from EC tumors using Iovance's proprietary 22-day Gen2 manufacturing process. Key parameters, including TIL yield, viability, immune phenotype, T-cell receptor clonality, and cytotoxic activity, were assessed. Of the 11 EC tumor samples processed at research scale, 10 (91%) successfully generated >1 × 10

Indexed as

Endometrial NeoplasmsImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingAgedCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesClinical Trials, Phase II as TopicFeasibility StudiesFemaleHumansMiddle Agedimmunotherapymismatch repairtumor-infiltrating lymphocytesuterine neoplasms

Identifiers

PMID40806287
PMCPMC12346291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.